Skip to Content

CAR-T Cell Therapy as Second-Line Treatment for Elderly Patients with Relapsed/Refractory Large B-Cell Lymphoma

Mats Jerkeman discusses in this MEDtalk the ZUMA-7 trial’s subgroup analysis from the ASH meeting. This trial compared CAR-T cell treatment to standard autologous stem cell transplant in first relapse diffuse large B-cell lymphoma (R/R LBCL) elderly patients (above 65, including those over 70). Zuma-7 shows that CAR-T cell therapy significantly improved progression-free and overall survival in this subgroup. This finding suggests CAR-T cell therapy as a viable second-line treatment for elderly R/R LBCL patients.

Mats Jerkeman

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top